OncoMatch/Clinical Trials/NCT05974449
Lactobacillus Vaginalis Capsules for Treatment of Vulvovaginal Atrophy in Young Breast Cancer Patients
Is NCT05974449 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Vaginal Lactobacillus capsules for breast cancer female.
Treatment: Vaginal Lactobacillus capsules — This study is a prospective, randomized controlled, phase II clinical study with a planned enrolment of 60 patients. The study focuses on the efficacy and safety of Lactobacillus vaginalis capsules for the prevention and/or treatment of vulvovaginal symptoms in young breast cancer patients receiving ovarian protection during chemotherapy, in order to improve compliance and quality of life in breast cancer patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Kidney function
serum creatinine < 1.5x uln
Liver function
ast and alt < 1.5x uln, alkaline phosphatase < 2.5x uln, total bilirubin < 1.5x uln
Cardiac function
lvef >= 50% on cardiac ultrasound
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify